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Introduction {#sec005}
============

Rheumatoid Arthritis (RA) is one of the most frequent chronic inflammatory rheumatism (CIR), characterized by chronic inflammation of joints, particularly hands and feet. The management of RA has been revolutionized with the development of biological disease-modifying antirheumatic drugs (bDMARD) \[[@pone.0220178.ref001],[@pone.0220178.ref002]\]. Mortality is increased in RA, especially due to cardiovascular diseases (CVD) \[[@pone.0220178.ref003],[@pone.0220178.ref004]\]. In a Danish population based study, the risk of CVD was similar between RA and diabetes (RR 1.7 95% CI 1.5 to 6.9 vs RR 1.7 95% CI 1.6 to 1.8, respectively, p = 0.64) \[[@pone.0220178.ref005]\]. The cardiovascular risk seems to be linked with the disease's activity. In a recent study, Arts & al showed that low disease activity (DAS28 ≤3.2) was associated with a reduced risk of CVD (HR 0.65 95% CI 0.43 to 0.99) compared with moderate or high disease activity (DAS28 \>3.2) \[[@pone.0220178.ref006]\].

The release of inflammatory cytokines (IL6, IL1, TNF alpha) leads to a decrease of total cholesterol (CT), especially HDL-cholesterol (HDL-C) \[[@pone.0220178.ref007],[@pone.0220178.ref008]\]. Furthermore, the anti-atherogenic function of HDL-cholesterol become pro-atherogenic because of a linkage with inflammatory proteins like SAA \[[@pone.0220178.ref008]\]. In the recent recommendations of the European Ligue Against Rheumatism (EULAR), CVD risk assessment is recommended for all patients with RA at least once every 5 years \[[@pone.0220178.ref009]\].

Tocilizumab (TCZ) is a bDMARD which blockades the IL-6 receptor and has demonstrated its efficacy to control the disease activity in a phase III double-blinded randomized controlled trial (RCT): the OPTION study \[[@pone.0220178.ref010]\]. However, RCT and other studies showed that TCZ was associated with an increased cholesterol level \[[@pone.0220178.ref010],[@pone.0220178.ref011]\]. This increase was also estimated superior compared to adalimumab (ADA) in a post-hoc analysis of the ADACTA trial \[[@pone.0220178.ref012]\]. TCZ interacts with CYP450 which is also implicated in atorvastatin metabolism \[[@pone.0220178.ref013]\]. Therefore, it has been used with caution in patients with high cardiovascular risk, particularly those with dyslipidemia. Recent studies showed reassuring data concerning major adverse cardiovascular events (MACE) with TCZ compared to other bDMARD \[[@pone.0220178.ref014]--[@pone.0220178.ref018]\]. Two studies conducted in American databases underscored significant decrease in cardiovascular events with TCZ \[[@pone.0220178.ref014],[@pone.0220178.ref015]\]. In Zhang & al. study, TCZ reduced the risk of myocardial infarction (MI) significantly more than abatacept (ABA) (HR 0.64 95% CI 0.41 to 0.99) \[[@pone.0220178.ref014]\]. Kim & al. found better cardiovascular outcomes with TCZ comparing to TNF inhibitors (TNFi) (HR 0.68 95% CI 0.49 to 0.94) \[[@pone.0220178.ref015]\]. Furthermore, TCZ decreases inflammatory proteins like SAA, and may restore the anti-atherogenic function of HDL-C.

Given these controversial results, we aimed to assess the cardiovascular safety of tocilizumab in rheumatoid arthritis compared to other bDMARD using a network meta-analysis (NMA).

Materials and methods {#sec006}
=====================

This systematic review with meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement (PRISMA) guidelines ([S1 File](#pone.0220178.s001){ref-type="supplementary-material"}) \[[@pone.0220178.ref019]\]. Our protocol was recorded on PROSPERO under the registration number CRD42018097180.

Literature search {#sec007}
-----------------

This systematic review was performed by searching in PubMed/Medline, Science Direct, and Web of Science databases, and in Cochrane and Wiley Online libraries. We also searched abstracts in the American College of Rheumatology (ACR) and European Ligue Against Rheumatism (EULAR) annual meetings databases, from January 2003 until May 2018. The search equations are available in supporting information ([S2 File](#pone.0220178.s002){ref-type="supplementary-material"}).

Eligibility criteria {#sec008}
--------------------

Our eligibility criteria for qualitative analysis were: RCT or observational (cohort only) studies, wrote in French or in English, assessing cardiovascular outcomes among rheumatoid arthritis patients treated by TCZ and/or ABA and/or rituximab (RTX) and/or TNFi.

Study selection {#sec009}
---------------

Studies were selected on the basis of their titles and abstracts, then on their full text, by two independent reviewers (BC, JM). Disagreements were resolved through discussion with a third reviewer (MV), when necessary.

Data extraction and quality assessment {#sec010}
--------------------------------------

Two reviewers (BC and JM) assessed independently the quality of selected studies using the Cochrane Risk Of Bias tool (RoB 2.0) \[[@pone.0220178.ref020]\] for randomized studies and the Cochrane Risk Of Bias In Non-randomized Studies---of Interventions (ROBINS-I tool) \[[@pone.0220178.ref021]\] for non-randomized. The two reviewers (BC and JM) also performed data extraction independently using a predetermined form. If necessary, disagreements were resolved by the third reviewer (MV). We extracted from each study: authors and publication year, country, bDMARD used in the study, number of previous bDMARD and previous csDMARD, number of patients, patient-year, follow-up period (year), number of MACE (major adverse cardiovascular events), myocardial infarction (MI), stroke, cardiac heart failure (CHF) and peripheral artery disease (PAD),

Outcomes measures {#sec011}
-----------------

The composite primary outcome was the rate of MACE which included stroke, MI, CHF and PAD (obliterating arteriopathy of the limbs, kidney and mesenteric artery diseases and aortic diseases. The secondary outcomes were rates of each cardiovascular event).

Data analysis {#sec012}
-------------

A frequentist network meta-analysis based on a random effects model \[[@pone.0220178.ref022]\] was conducted for all outcomes to compute relative risk (RR) and their 95% confidence interval (95%CI). NMA allows to synthesize information from numerous studies addressing the same outcomes but involving different interventions \[[@pone.0220178.ref023],[@pone.0220178.ref024]\]. NMA combines direct and indirect evidence across a network of studies into a single effect size. Forest plots were used to represent the quantitative results. For pairwise comparison, statistical heterogeneity between studies was assessed by the Cochran's Q test (p\<0.05 for significativity) and the I^2^ statistic (\<25%: low heterogeneity, 25--50%: moderate, 50--75%: high and \>75%: very high). All analyses were performed using R (netmeta package version 0.9--5 for treatment comparison, meta package version 4.8--2, R Language and Environment for Statistical Computing, Vienna, Austria) \[[@pone.0220178.ref025],[@pone.0220178.ref026]\]. A subgroup analysis was performed, including RCTs only and cohort studies only.

Results {#sec013}
=======

Literature search results and studies characteristics {#sec014}
-----------------------------------------------------

After duplicates removal, 10 454 articles were found using PubMed/Medline, Science direct, Web of science, Cochrane library databases and ACR and EULAR conference abstracts. Of the 10 454 identified records, 10 319 were excluded at title/abstract level, leaving 135 full-text examined. Of these, we selected 29 studies, 27 original articles and two conference abstracts \[[@pone.0220178.ref018],[@pone.0220178.ref027]\] for qualitative analysis ([Fig 1](#pone.0220178.g001){ref-type="fig"}). 106 articles did not meet the inclusion criteria for the following reasons: one was a case-control study, 55 were not controlled studies, 44 did not have clinical outcomes (biological or imaging), five because the studied population was already included, and one because the full-test could not be accessed.

![Flow chart of the systematic literature review.\
PubMed/Medline, Web of science, Cochrane library, Science direct and ACR, Annual College of Rheumatology; EULAR, European League Against Rheumatism databases.](pone.0220178.g001){#pone.0220178.g001}

Of the 29 studies included in the qualitative analysis, 13 studies were conducted in North America \[[@pone.0220178.ref011],[@pone.0220178.ref014],[@pone.0220178.ref015],[@pone.0220178.ref017],[@pone.0220178.ref028]--[@pone.0220178.ref035]\], 16 in Europe \[[@pone.0220178.ref010],[@pone.0220178.ref011],[@pone.0220178.ref017],[@pone.0220178.ref018],[@pone.0220178.ref029],[@pone.0220178.ref034],[@pone.0220178.ref036]--[@pone.0220178.ref045]\], five in Asia \[[@pone.0220178.ref017],[@pone.0220178.ref032],[@pone.0220178.ref046]--[@pone.0220178.ref048]\], four in South America \[[@pone.0220178.ref011],[@pone.0220178.ref017],[@pone.0220178.ref034],[@pone.0220178.ref038]\] and two in Australia \[[@pone.0220178.ref011],[@pone.0220178.ref032]\]. Study characteristics are available in [Table 1](#pone.0220178.t001){ref-type="table"}. 16/29 studies were RCT \[[@pone.0220178.ref010],[@pone.0220178.ref011],[@pone.0220178.ref027],[@pone.0220178.ref029],[@pone.0220178.ref032],[@pone.0220178.ref034]--[@pone.0220178.ref036],[@pone.0220178.ref039],[@pone.0220178.ref041]--[@pone.0220178.ref046],[@pone.0220178.ref048]\]and 13/29 were cohort studies \[[@pone.0220178.ref014],[@pone.0220178.ref015],[@pone.0220178.ref017],[@pone.0220178.ref018],[@pone.0220178.ref028],[@pone.0220178.ref030],[@pone.0220178.ref031],[@pone.0220178.ref033],[@pone.0220178.ref037],[@pone.0220178.ref038],[@pone.0220178.ref040],[@pone.0220178.ref047],[@pone.0220178.ref049]\]. Of the 13 cohort studies, five \[[@pone.0220178.ref014],[@pone.0220178.ref015],[@pone.0220178.ref017],[@pone.0220178.ref031],[@pone.0220178.ref033]\] were performed using national health care databases and four \[[@pone.0220178.ref014],[@pone.0220178.ref015],[@pone.0220178.ref031],[@pone.0220178.ref033]\] were propensity matched. Of the 16 RCT, four were open-label trials \[[@pone.0220178.ref027],[@pone.0220178.ref041],[@pone.0220178.ref043],[@pone.0220178.ref046]\], the others were double-blinded.

10.1371/journal.pone.0220178.t001

###### Characteristics and results of studies on cardiovascular events (n = 29).

![](pone.0220178.t001){#pone.0220178.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  STUDY                                             TREATMENT                          AGE (YEARS)      GENDER (FEMALE)   HTA     DYSLIPIDEMIA   SMOKING   DIABETUS MIELLETUS   PREV CV   PREVB   PREVCS   N        TOTAL PY   FOLLOW-UP (YEAR)   MACE   MI    STROKE   CHF
  ------------------------------------------------- ---------------------------------- ---------------- ----------------- ------- -------------- --------- -------------------- --------- ------- -------- -------- ---------- ------------------ ------ ----- -------- -----
  **AL-ALY &AL.** \[[@pone.0220178.ref028]\]\       TNFi                               57 ±12           9%                68%     52%            NS        31%                  38%       NS      NS       3796     9 563      3.5                1460   NS    NS       NS
  **2011**                                                                                                                                                                                                                                                              

  csDMARD                                           63 ±12                             9%               68%               52%     NS             31%       36%                  NS        NS      19899    65 766   3.5        7761               NS     NS    NS       

  **BURMESTER &AL.** \[[@pone.0220178.ref036]\]\    TCZ                                50.2±13.6        77%               NS      NS             NS        NS                   NS        0       0        1 108    1 645      2                  NS     NS    NS       NS
  **2017**                                                                                                                                                                                                                                                              

  MTX                                               49.6\                              80%              NS                NS      NS             NS        NS                   0         0       282      339      2          NS                 NS     NS    NS       
                                                    ±13.1                                                                                                                                                                                                               

  **CARDENAS &AL.** \[[@pone.0220178.ref037]\]\     IFX                                51.5 ±12.7       80%               NS      NS             NS        NS                   NS        0       1        55       NS         2                  3      NS    NS       NS
  **2016**                                                                                                                                                                                                                                                              

  ADA                                               52.9 ±14.7                         87%              NS                NS      NS             NS        NS                   0         1       31       NS       2          1                  NS     NS    NS       

  ETN                                               55.1\                              82%              NS                NS      NS             NS        NS                   0         1       44       NS       2          3                  NS     NS    NS       
                                                    ±14                                                                                                                                                                                                                 

  **CHOY &AL.** \[[@pone.0220178.ref038]\]\         TCZ                                54.3\            NS                NS      NS             NS        NS                   NS        0       1        423      404        1                  0      NS    0        NS
  **2017**                                                                             ±12.8                                                                                                                                                                            

  TNFi                                              55.2\                              NS               NS                NS      NS             NS        NS                   0         1       793      776      1          2                  NS     2     NS       
                                                    ±13.1                                                                                                                                                                                                               

  **CURTIS &AL.** \[[@pone.0220178.ref017]\]\       TCZ (insurance claims databases)   NS               NS                NS      NS             NS        NS                   NS        NS      NS       62 713   60 754     NS                 206    115   91       NS
  **2015**                                                                                                                                                                                                                                                              

  TNFi                                              NS                                 NS               NS                NS      NS             NS        NS                   NS        NS      19 000   53 360   NS         676                308    368   NS       

  TCZ (safety database)                             NS                                 NS               NS                NS      NS             NS        NS                   NS        NS      5 734    4 345    NS         28                 14     14    NS       

  **EMERY &AL.** \[[@pone.0220178.ref029]\]\        CTZ                                50.4 ±13.6       76%               NS      NS             NS        NS                   NS        0       0        659      NS         1                  39     NS    NS       NS
  **2010**                                                                                                                                                                                                                                                              

  MTX                                               51.2 ±13                           80%              NS                NS      NS             NS        NS                   0         0       213      NS       1          9                  NS     NS    NS       

  **EMERY &AL.** \[[@pone.0220178.ref039]\]\        RTX                                51.6\            80.4%             NS      NS             NS        NS                   NS        0       1        337      161        0.5                4      NS    NS       NS
  **2017**                                                                             ±12.7                                                                                                                                                                            

  MTX                                               52.16±12.4                         85.5%            NS                NS      NS             NS        NS                   0         1       172      79       0.5        13                 NS     NS    NS       

  **GABAY &AL.** \[[@pone.0220178.ref011]\]\        TCZ                                54.4 ±13         79%               NS      NS             NS        NS                   NS        0       1        162      NS         0.5                3      2     1        NS
  **2013**                                                                                                                                                                                                                                                              

  ADA                                               53.3 ±12.4                         82%              NS                NS      NS             NS        NS                   0         1       162      NS       0.5        2                  1      1     NS       

  **GEBOREK&AL.** \[[@pone.0220178.ref049]\]\       ETN                                54               78%               NS      NS             NS        NS                   NS        0       2        166      NS         NS                 4      4     0        0
  **2002**                                                                                                                                                                                                                                                              

  IFX                                               55.4                               79%              NS                NS      NS             NS        NS                   0         2       135      NS       NS         0                  0      0     0        

  csDMARD                                           61.3                               82%              NS                NS      NS             NS        NS                   0         2       103      NS       NS         0                  0      0     0        

  **GILES &AL.** \[[@pone.0220178.ref027]\]\        TCZ                                61               78%               71%     NS             29%       18%                  NS        0       1        1538     4900       3.2                83     29    26       12
  **2016**                                                                                                                                                                                                                                                              

  ETN                                               0                                  12               1542              4891    3.2            78        32                   16        8                                                                             

  **GOTTENBERG &AL.** \[[@pone.0220178.ref018]\]\   TCZ                                NS               NS                NS      NS             NS        NS                   NS        NS      NS       NS       3 441      2                  NS     NS    NS       NS
  **2016**                                                                                                                                                                                                                                                              

  ABA                                               NS                                 NS               NS                NS      NS             NS        NS                   NS        NS      NS       4 912    2          NS                 NS     NS    NS       

  RTX                                               NS                                 NS               NS                NS      NS             NS        NS                   NS        NS      NS       10 545   2          NS                 NS     NS    NS       

  **HARROLD &AL.** \[[@pone.0220178.ref030]\]\      RTX                                57.8 ±11.7       81%               NS      NS             NS        9.8%                 11.3%     ≧1      NS       265      242        1                  5      NS    NS       NS
  **2015**                                                                                                                                                                                                                                                              

  TNFi                                              56.1 ±12.4                         79%              NS                NS      NS             10.7%     7.3%                 ≧1        NS      205      737      1          9                  NS     NS    NS       

  **IANNONE &AL.** \[[@pone.0220178.ref040]\]\      TCZ                                54.5                               14.3%   NS             NS        3.9%                 3.5%      NS      NS       202      NS         2                  7      NS    NS       NS
  **2017**                                                                                                                                                                                                                                                              

  ABA                                               57.4                               77.2%            15.3%             NS      NS             2.9%      4.7%                 NS        NS      230      NS       2          11                 NS     NS    NS       

  TNFi                                              53,9                                                23.2%             NS      NS             4.9%      5%                   NS        NS      1 135    NS       2          33                 NS     NS    NS       

  **JIN &AL.** \[[@pone.0220178.ref031]\]\          ABA                                NS               NS                NS      NS             NS        NS                   NS        NS      NS       6934     NS         NS                 114    NS    NS       NS
  **2017**                                                                                                                                                                                                                                                              

  TNFi                                              NS                                 NS               NS                NS      NS             NS        NS                   NS        NS      6934     NS       NS         113                NS     NS    NS       

  **JOBANPUTRA &AL.** \[[@pone.0220178.ref041]\]\   ADA                                55 ±12.5         75%               NS      NS             NS        NS                   NS        0       2        60       NS         1                  5      NS    NS       NS
  **2012**                                                                                                                                                                                                                                                              

  ETN                                               53.2 ±12.4                         70%              NS                NS      NS             NS        NS                   0         2       60       NS       1          6                  NS     NS    NS       

  **KAY &AL.** \[[@pone.0220178.ref042]\]\          GOL                                54 (46--64)      77.4%             NS      NS             NS        NS                   NS        0       1        137      NS         1                  2      NS    NS       2
  **2008**                                                                                                                                                                                                                                                              

  MTX                                               52 (46--66)                        74.3%            NS                NS      NS             NS        NS                   0         1       35       NS       1          0                  NS     NS    0        

  **KEYSTONE &AL.** \[[@pone.0220178.ref032]\]\     GOL                                51 (44--57)      89%               NS      NS             NS        NS                   NS        0       1        434      NS         5                  2      2     NS       NS
  **2016**                                                                                                                                                                                                                                                              

  MTX                                               52 (42--58)                        82%              NS                NS      NS             NS        NS                   0         1       105      NS       5          0                  0      NS    NS       

  **KIM &AL.** \[[@pone.0220178.ref046]\]\          ETN                                48.4 ±12         91.4%             NS      NS             NS        NS                   NS        0       0        137      NS         0.33               1      NS    NS       1
  **2012**                                                                                                                                                                                                                                                              

  csDMARD                                           48.5 ±11.3                         88.4%            NS                NS      NS             NS        NS                   0         0       103      NS       0.33       0                  NS     NS    0        

  **KIM &AL.** \[[@pone.0220178.ref015]\]\          TCZ                                58.9 ±10,2       88,3%             60,6%   45,8%          NS        20%                  12,5%     ≧1      NS       9 218    7 236      NS                 43     21    23       NS
  **2017**                                                                                                                                                                                                                                                              

  TNFi                                              58.7 ±10                           82%              57,5%             44%     NS             16%       12.2%                ≧1        NS      18 810   14 776   NS         103                7      49    NS       

  **KIM &AL.** \[[@pone.0220178.ref033]\]\          TCZ                                58,8 ±10,4       81,4%             59,8%   46.3%          NS        20,1%                12%       NS      NS       6 237    N\         NS                 32     NS    NS       NS
  **2018**                                                                                                                                                                                                          S                                                   

  ABA                                               59 ±10                             87%              59,1%             45.4%   NS             19,23%    12,6                 NS        NS      14 685   NS       NS         112                NS     NS    NS       

  **MANDERS &AL.** \[[@pone.0220178.ref043]\]\      ABA                                56.2 ±9.95       88.4%             NS      NS             NS        NS                   NS        1       1        43       NS         1                  1      NS    NS       NS
  **2015**                                                                                                                                                                                                                                                              

  RTX                                               57.1 ±11.1                         63%              NS                NS      NS             NS        NS                   1         1       46       NS       1          2                  NS     NS    NS       

  TNFi                                              56.3 ±11.2                         74%              NS                NS      NS             NS        NS                   1         1       50       NS       1          2                  NS     NS    NS       

  **SAKAI & AL.** \[[@pone.0220178.ref047]\]\       TCZ                                59.2 ±13         82.5%             NS      NS             NS        10.9%                NS        NS      NS       302      224,68     1                  NS     NS    NS       NS
  **2015**                                                                                                                                                                                                                                                              

  TNFi                                              57.33 ±15.2                        82.8%            NS                NS      NS             10.5%     NS                   NS        NS      304      231,01   1          NS                 NS     NS    NS       

  **SMOLEN &AL.** \[[@pone.0220178.ref044]\]\       CTZ                                53.6 ±11.9       86.4%             NS      NS             NS        NS                   NS        0       1        96       NS         2                  9      NS    NS       NS
  **2015**                                                                                                                                                                                                                                                              

  csDMARD                                           54 ±12.4                           76.4%            NS                NS      NS             NS        NS                   0         1       98       NS       2          5                  NS     NS    NS       

  **SMOLEN &AL.** \[[@pone.0220178.ref045]\]\       CTZ                                53.5 ±12.3       79%               NS      NS             NS        NS                   NS        0       1        516      NS         2                  12     NS    NS       9
  **2016**                                                                                                                                                                                                                                                              

  ADA                                               52.9 ±12.8                         79%              NS                NS      NS             NS        NS                   0         1       523      NS       2          9                  NS     NS    8        

  **SMOLEN &AL.** \[[@pone.0220178.ref010]\]\       TCZ                                51.1 ±12.3       83.5%             NS      NS             NS        NS                   NS        0       1        418      NS         1                  29     NS    NS       NS
  **2008**                                                                                                                                                                                                                                                              

  MTX                                               50.6 ±12.1                         78%              NS                NS      NS             NS        NS                   0         1       204      NS       1          10                 NS     NS    NS       

  **WESTHOVENS &AL.** \[[@pone.0220178.ref034]\]\   IFX                                52.5 (44_60.5)   78.9              NS      NS             NS        NS                   NS        0       1        721      NS         0.5                5      4     1        NS
  **2006**                                                                                                                                                                                                                                                              

  MTX                                               52 (44--61)                        83.2%            NS                NS      NS             NS        NS                   0         1       363      NS       0.5        0                  0      0     NS       

  **WEISMAN &AL.** \[[@pone.0220178.ref035]\]\      ETN                                60.6 (19--84)    72.2%             63.5%   63.5%          NS        49.7%                60%       0       1        266      NS         0.33               7      NS    NS       NS
  **2007**                                                                                                                                                                                                                                                              

  Placebo                                           59.2 (23--85)                      78.1%            56.1%             66.1%   NS             49.5%     65%                  0         1       269      NS       0.33       1                  NS     NS    NS       

  **YAMAMOTO &AL.** \[[@pone.0220178.ref048]\]\     CTZ                                53.4 v±10.7      81.9%             NS      NS             NS        NS                   NS        0       1        239      NS         0.5                2      2     NS       NS
  **2014**                                                                                                                                                                                                                                                              

  MTX                                               51.9 ±11.1                         85.7%            NS                NS      NS             NS        NS                   0         1       77       NS       0.5        0                  0      NS    NS       

  **ZHANG &AL.** \[[@pone.0220178.ref014]\]\        TCZ                                63.7             87%               27.8%   NS             23.59%    14.1%                NS        NS      NS       3 332    2 728      NS                 17     17    NS       NS
  **2016**                                                                                                                                                                                                                                                              

  RTX                                               64.9                               84.4%            30%               NS      21.55%         14.84%    NS                   NS        NS      7 475    8 424    NS         71                 71     NS    NS       

  TNFi                                              67.5%                              86.7%            27.7%             NS      21.19%         15%       NS                   NS        NS      35 718   44 763   NS         359                359    NS    NS       

  ABA                                               65.6                               87%              29.6%             NS      22.1%          13.9%     NS                   NS        NS      13 608   18 747   NS         138                138    NS    NS       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RTX, rituximab; ADA, adalimumab; IFX, infliximab; ETN, etanercept; CTZ, certolizumab pegol; GOL, golimumab; MTX, methotrexate; TNFi, TNF inhibitor; Prevcs, previous csDMARD, conventional synthetic disease-modifying antirheumatic drugs; PrevB, previous bDMARD biological disease-modifying antirheumatic drugs; PrevCV, previous cardiovascular event; NS, not specified; PY, patient year

We identify two major concerns due to cofounding in two cohort studies \[[@pone.0220178.ref040],[@pone.0220178.ref049]\], because of the absence of multivariate analysis. The other potential bias was selective reporting due to the absence of online recorded protocol for 8 studies. Detailed bias assessment is reported in [Table 2](#pone.0220178.t002){ref-type="table"}.

10.1371/journal.pone.0220178.t002

###### Risk of bias assessment (n = 29).

![](pone.0220178.t002){#pone.0220178.t002g}

  -------------------------------------------- ---------- ------------------------- ---------------------------------------- ------------------------------------------- ------------------------------------------------ --------------------------------- ----------------------------- -------------------------
  Randomized controlled Trial (ROB2 tool)                                                                                                                                                                                                                                                 

  **Author**                                   **Year**   **Study acronym**         **Random sequence generation**           **Allocation concealment**                  **Blinding of particpants and personnel**        **Blinding of outcome data**      **Incomplete outcome data**   **Selective reporting**

  Burmester &al. \[[@pone.0220178.ref036]\]    2017       FUNCTION                  $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
                                                                                     + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Emery &al. \*\                               2010       SERENE                    $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref029]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Emery &al. \*\                               2017       C-EARLY                   $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref039]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Gabay &al. \*\                               2013       ADACTA                    $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref011]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Giles &al. \*\                               2016       \-                        $\begin{matrix}                          $\begin{matrix}                             $?$                                              $?$                               $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref027]\]                                                         + \\                                     + \\                                                                                                                           + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                                                                                                                  \end{matrix}$                 \end{matrix}$

  Jobanputra &al.\                             2012       RED SEA                   $\begin{matrix}                          $\begin{matrix}                             $?$                                              $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref041]\]                                                         + \\                                     + \\                                                                                         + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                                                                                \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Kay &al. \*\                                 2008       \-                        $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref042]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Keystone &al.\*\                             2016       GO-FORWARD                $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref032]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Kim &al. \*\                                 2012       APPEAL                    $\begin{matrix}                          $\begin{matrix}                             $?$                                              $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref046]\]                                                         + \\                                     + \\                                                                                         + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                                                                                \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Manders &al. \*\                             2015       DREAM-TIME                $\begin{matrix}                          $\begin{matrix}                             $?$                                              $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref043]\]                                                         + \\                                     + \\                                                                                         + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                                                                                \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Smolen &al. \*\                              2008       OPTION                    $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref010]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Smolen &al.\                                 2016       EXXELARATE                $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref045]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Smolen &al. \*\                              2015       CERTAIN                   $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref044]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Westhovens &al. \*\                          2006       \-                        $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref034]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Weisman &al.\                                2007       \-                        $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref035]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Yamamoto &al. \*\                            2014       J-RAPID                   $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref048]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Non randomized trials(ROBINS-I tool)                                                                                                                                                                                                                                                    

  **Author**                                   **Year**   **Bias due cofounding**   **Bias in selection of participatnts**   **Bias in classification of interventio**   **Bias due to deviations froms interventions**   **Bias in measurement outcome**   **Incomplete outcome data**   **Selective reporting**

  Al-aly &al.\*\                               2011       ****$?$****               $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $?$
  \[[@pone.0220178.ref028]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                         
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 

  Cardenas &al.\                               2016       $?$                       $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $?$
  \[[@pone.0220178.ref037]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                         
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 

  Choy &al. \*\                                2017       $?$                       $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
  \[[@pone.0220178.ref038]\]                                                         + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Curtis &al. \[[@pone.0220178.ref017]\]       2015       $?$                       $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
                                                                                     + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Geborek &al. \* \[[@pone.0220178.ref049]\]   2002       ****$-$****               $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $?$
                                                                                     + \\                                     + \\                                        + \\                                             + \\                              + \\                         
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 

  Gottenberg &al. \[[@pone.0220178.ref018]\]   2016       $?$                       $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $?$
                                                                                     + \\                                     + \\                                        + \\                                             + \\                              + \\                         
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 

  Harrold &al. \* \[[@pone.0220178.ref030]\]   2015       $?$                       $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               ****$\begin{matrix}
                                                                                     + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$****

  Iannone &al. \* \[[@pone.0220178.ref040]\]   2018       ****$-$****               $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $?$
                                                                                     + \\                                     + \\                                        + \\                                             + \\                              + \\                         
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 

  Jin &al. \[[@pone.0220178.ref031]\]          2017       $\begin{matrix}           $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $?$
                                                           + \\                      + \\                                     + \\                                        + \\                                             + \\                              + \\                         
                                                          \end{matrix}$             \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 

  Kim &al. \[[@pone.0220178.ref015]\]          2017       $\begin{matrix}           $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
                                                           + \\                      + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                          \end{matrix}$             \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Kim &al. \* \[[@pone.0220178.ref033]\]       2018       $\begin{matrix}           $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $\begin{matrix}
                                                           + \\                      + \\                                     + \\                                        + \\                                             + \\                              + \\                          + \\
                                                          \end{matrix}$             \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 \end{matrix}$

  Sakai &al. \[[@pone.0220178.ref047]\]        2015       ****$?$****               $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $?$
                                                                                     + \\                                     + \\                                        + \\                                             + \\                              + \\                         
                                                                                    \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 

  Zhang &al. \* \[[@pone.0220178.ref014]\]     2016       ****$\begin{matrix}       $\begin{matrix}                          $\begin{matrix}                             $\begin{matrix}                                  $\begin{matrix}                   $\begin{matrix}               $?$
                                                           + \\                      + \\                                     + \\                                        + \\                                             + \\                              + \\                         
                                                          \end{matrix}$****         \end{matrix}$                            \end{matrix}$                               \end{matrix}$                                    \end{matrix}$                     \end{matrix}$                 
  -------------------------------------------- ---------- ------------------------- ---------------------------------------- ------------------------------------------- ------------------------------------------------ --------------------------------- ----------------------------- -------------------------

RTX, rituximab; ADA, adalimumab; IFX, infliximab; ETN, etanercept; CTZ, certolizumab pegol; GOL, golimumab; MTX, methotrexate; TNFi, TNF inhibitor; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; NS, not specified, PY; patient year; IR incidence rate; RCT randomized controlled trial; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; + low risk; ? some concerns; − high risk; \*, included in NMA

For quantitative analysis, analyzable data for NMA were available in only 19 studies for MACE outcome \[[@pone.0220178.ref010],[@pone.0220178.ref011],[@pone.0220178.ref014],[@pone.0220178.ref027]--[@pone.0220178.ref030],[@pone.0220178.ref032]--[@pone.0220178.ref034],[@pone.0220178.ref038]--[@pone.0220178.ref040],[@pone.0220178.ref042]--[@pone.0220178.ref044],[@pone.0220178.ref046],[@pone.0220178.ref048],[@pone.0220178.ref049]\], eight for MI \[[@pone.0220178.ref011],[@pone.0220178.ref014],[@pone.0220178.ref015],[@pone.0220178.ref027],[@pone.0220178.ref032],[@pone.0220178.ref034],[@pone.0220178.ref048],[@pone.0220178.ref049]\], five for stroke \[[@pone.0220178.ref011],[@pone.0220178.ref015],[@pone.0220178.ref027],[@pone.0220178.ref034],[@pone.0220178.ref038]\], but not enough data were available for CHF. Unfortunately, PAD was included in the MACE composite criteria in the studies but were not reported separately. Three studies \[[@pone.0220178.ref018],[@pone.0220178.ref036],[@pone.0220178.ref047]\] responded to our inclusion criteria but did not reported the number of MACE event, only Hazard Ratio (HR) or only the total number or cardiovascular events (not for each group) which have not been reported in [Table 1](#pone.0220178.t001){ref-type="table"}.

MACE risk with TCZ vs other bDMARD {#sec015}
----------------------------------

The analysis of MACE outcome encompassed 19 studies (11 RCT and 8 cohorts) 12 312 patients were treated by TCZ, 8 123 with RTX, 28 728 with ABA, 45 963 with TNFi and 21 372 with csDMARD. 1 766 MACE were recorded: 125 under TCZ (1.02%), 183 under RTX (2.25%), 656 under ABA (2.28%), 1066 under TNFi (2.32%), 264 under csDMARD (1.24%).

First, we included only RCT (n = 11) in the NMA. We found less events with RTX (TCZ vs RTX 5.41 \[1.70;17.26\]. We found no difference between TCZ and other treatments (1.10 \[0.50;2.40\] with TNFi, 4.37 \[0.43;44.55\] with ABA and 1.49\[0.77;17.26\] with csDMARD) ([Fig 2](#pone.0220178.g002){ref-type="fig"}). The results with only observational studies are represented in [Fig 3](#pone.0220178.g003){ref-type="fig"}.

When we included both designs (RCT and cohort) we found no difference between TCZ and other treatments: 0.66 \[0.42;1.03\] with ABA, 1.04 \[0.60;1.81\] with RTX, 0.78\[0.53;1.16\] and 0.91 \[0.54;1.51\] with csDMARD ([Fig 4](#pone.0220178.g004){ref-type="fig"}).

![NMA with RCT on major adverse cardiac events, myocardial infarction and stroke with TCZ vs other treatments.\
comparison---Treatment comparison, k---Number of studies providing direct evidence, prop---Direct evidence proportion, nma---Estimated treatment effect (RR) in network meta-analysis, direct---Estimated treatment effect (RR) derived from direct evidence, indirect---Estimated treatment effect (RR) derived from indirect evidence, RoR---Ratio of Ratios (direct versus indirect), p-value---p-value of test for disagreement (direct versus indirect), TCZ---tocilizumab; csDMARDs---conventional synthetic disease-modifying antirheumatic drugs; TNFi---tumor necrosis factor inhibitor; ABA---abatacept; RTX---rituximab.](pone.0220178.g002){#pone.0220178.g002}

![NMA with cohort studies on major adverse cardiac events, myocardial infarction and stroke with TCZ vs other treatments.\
comparison---Treatment comparison, k---Number of studies providing direct evidence, prop---Direct evidence proportion, nma---Estimated treatment effect (RR) in network meta-analysis, direct---Estimated treatment effect (RR) derived from direct evidence, indirect---Estimated treatment effect (RR) derived from indirect evidence, RoR---Ratio of Ratios (direct versus indirect), p-value---p-value of test for disagreement (direct versus indirect), TCZ---tocilizumab; csDMARDs---conventional synthetic disease-modifying antirheumatic drugs; TNFi---tumor necrosis factor inhibitor; ABA---abatacept; RTX---rituximab.](pone.0220178.g003){#pone.0220178.g003}

![NMA with both designs (RCT and cohorts) on major adverse cardiac events, myocardial infarction and stroke with TCZ vs other treatments.\
comparison---Treatment comparison, k---Number of studies providing direct evidence, prop---Direct evidence proportion, nma---Estimated treatment effect (RR) in network meta-analysis, direct---Estimated treatment effect (RR) derived from direct evidence, indirect---Estimated treatment effect (RR) derived from indirect evidence, RoR---Ratio of Ratios (direct versus indirect), p-value---p-value of test for disagreement (direct versus indirect), TCZ---tocilizumab; csDMARDs---conventional synthetic disease-modifying antirheumatic drugs; TNFi---tumor necrosis factor inhibitor; ABA---abatacept; RTX---rituximab.](pone.0220178.g004){#pone.0220178.g004}

MI risk with TCZ vs other bDMARD {#sec016}
--------------------------------

The analysis of MI risk included eight studies (four RCT and four cohorts). 11 723 patients were treated by TCZ, 74 75 with RTX, 13 608 with ABA, 53 068 with TNFi and 648 with csDMARD. 689 MI were recorded, 58 under TCZ (0.49%), 71 under RTX (0.95%), 138 under ABA (1.01%) and 422 under TNFi (0.80%) and no MI under csDMARD. In the RCT NMA we found no difference between TCZ and csDMARD (4.23 \[0.22;80.64\]), no difference between TCZ and TNFi (2.00 \[0.18;21.84\]). We lacked data to compare TCZ and other bDMARD ([Fig 2](#pone.0220178.g002){ref-type="fig"}). With both designs included, the risk of myocardial infarction was lower with TCZ compared to ABA (0.67 \[0.47;0.97\]). There was no difference with other treatments ([Fig 4](#pone.0220178.g004){ref-type="fig"}).

Stroke risk with TCZ vs other bDMARD {#sec017}
------------------------------------

Five studies were included for stroke event (two RCT and three cohorts). 11 345 patients were treated by TCZ, 22 024 by TNFi and 363 by csDMARD. 119 strokes were recorded, 40 under TCZ (0.35%), 79 under TNFi (0.36%). We did not record stroke event under csDMARD only. With RCT NMA, there was no difference between TCZ and csDMARD (1.51\[0.02;103.50\] and between TCZ and TNFi (1.00 \[0.06;15.85\]). We lacked data to compare TCZ and other bDMARD ([Fig 2](#pone.0220178.g002){ref-type="fig"}). Similar results were found with the analysis that included both designs ([Fig 4](#pone.0220178.g004){ref-type="fig"}), and with observational studies only ([Fig 3](#pone.0220178.g003){ref-type="fig"}).

Comparison of CHF {#sec018}
-----------------

There was not enough data available to perform a network meta-analysis.

Discussion {#sec019}
==========

We performed the first network meta-analysis comparing the cardiovascular outcomes of TCZ and other biologics. However, we found a lower risk of MACE with RTX in the RCT NMA, which is not significant when we included only cohorts or both designs. This study showed that TCZ has similar cardiovascular outcomes comparing with other bDMARD and csDMARD.

TCZ significantly increases lipids levels more than TNFi \[[@pone.0220178.ref012]\], ABA and RTX \[[@pone.0220178.ref050]\]. This is one of the reasons why TCZ was initially used with a particular attention in patient with a high cardiovascular risk. Despite this increase, our results show the cardiovascular safety profile of TCZ comparing to the other biologics, especially when we included only RCT in the NMA. We also found less myocardial infarction with TCZ than ABA and TNFi in observational studies. This beneficial effect on myocardial infarction could be explained by the fact that TCZ decreases more lipoprotein A levels, and SAA-HDL than adalimumab in the ADACTA study \[[@pone.0220178.ref012]\]. Indeed, lipoprotein-A has been associated with MI \[[@pone.0220178.ref051]\] and the HDL linkage by SSA protein could be responsible for HDL-C loss anti atherogenic function \[[@pone.0220178.ref012],[@pone.0220178.ref050],[@pone.0220178.ref052],[@pone.0220178.ref053]\]. Furthermore, inflammatory cytokines, particularly IL-1 and IL-6 seem to play a determinant role in the atherosclerotic process. Recently, the CANTOS trial performed in general population shown a significantly lower rate of recurrent cardiovascular events with canakinumab than placebo \[[@pone.0220178.ref054]\]. A cohort study found an improvement of the endothelial function in high risk patients with RA with TCZ but not with TNFi \[[@pone.0220178.ref055]\]. IL-6 seems strongly involved in the coronary heart disease (CHD), especially via the trans-signaling pathway \[[@pone.0220178.ref056]--[@pone.0220178.ref058]\]. Mendelian randomization studies showed that IL-6 up-regulation increases CHD risk \[[@pone.0220178.ref059],[@pone.0220178.ref060]\]. Conversely, the variant Asp358 causes an increase in the soluble IL-6 receptor (IL-6Rs) and is associated with a reduced risk of coronary artery disease \[[@pone.0220178.ref061],[@pone.0220178.ref062]\]. Indeed, in a placebo-RCT in general population with MI, a single dose of TCZ decreases more troponin levels than placebo at day 3 \[[@pone.0220178.ref063]\]. In an observational study Kobayashi & al. found that TCZ treatment in RA patients significantly increased left ventricular ejection fraction and decreased left ventricular mass index comparing to healthy controls \[[@pone.0220178.ref064]\]. Finally, in high-risk population of CHD, high IL-6 levels were associated with MI risk, cardiovascular death and all causes death \[[@pone.0220178.ref065]\].

This systematic review and meta-analysis have several strengths. Indeed, we performed an exhaustive review, through four international databases, and two international meetings databases. The included studies showed high quality. RCT were at low risk of bias except for which who were open-label. However, one of these had MACE as primary outcome with an open-label design. Furthermore this study is not published and was found in the 2016 ACR meetings abstract \[[@pone.0220178.ref016]\]. Most of the cohort studies were at "moderate risk of bias" only because of their non-randomized design. We realized a network meta-analysis which allowed us to make indirect comparisons of multiple treatments and thus to analyze a large amount of studies including placebo RCT. Due to multiple comparators, heterogeneity had to be measured which was possible with this technique. Furthermore, we used random effects model even if the heterogeneity test was no statistically significant because it considers fluctuations of sampling and also treatment effect fluctuations due to multiple covariates. Finally, although we restricted our research to English and French languages, no article was excluded because of the language.

However, our studies showed some limits. The heterogeneity test was significant for MACE outcome which was controlled by using a random effects model. The transivity hypothesis has not been tested, which is a limitation of the study. Unfortunately, the baseline CV risk was not specified in the included studies, we were unable to carry out an analysis to determine whether this risk was an effect modifier.

Our network meta-analysis illustrates the indication bias in observational studies. Indeed, the beneficial effect of TCZ for MI could be explained by a lesser use of TCZ in high CV risk patients because of the cholesterol increase under treatment. The fact that TCZ is under used in high-risk CV patients is not supported by the literature, the indication bias due to the prudent use of TCZ in high-risk patients is therefore purely hypothetical, not supported by the literature, but remains likely. Another explanation is that observational studies were designed to study cardiovascular events, with high sample sizes, unlike RCTs.

Conclusion {#sec020}
==========

Despite these limits, our study showed a good cardiovascular safety profile of TCZ compared to other bDMARD, with potential benefit on MI compared to other bDMARD. Further studies are needed to corroborate these data.
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